EW vs. ABT, ISRG, SYK, BSX, MDT, BDX, DXCM, IDXX, RMD, and STE
Should you be buying Edwards Lifesciences stock or one of its competitors? The main competitors of Edwards Lifesciences include Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), and STERIS (STE). These companies are all part of the "health care equipment" industry.
Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Edwards Lifesciences received 392 more outperform votes than Abbott Laboratories when rated by MarketBeat users. Likewise, 71.85% of users gave Edwards Lifesciences an outperform vote while only 69.64% of users gave Abbott Laboratories an outperform vote.
Edwards Lifesciences has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.
In the previous week, Abbott Laboratories had 3 more articles in the media than Edwards Lifesciences. MarketBeat recorded 23 mentions for Abbott Laboratories and 20 mentions for Edwards Lifesciences. Edwards Lifesciences' average media sentiment score of 0.94 beat Abbott Laboratories' score of 0.54 indicating that Edwards Lifesciences is being referred to more favorably in the media.
Edwards Lifesciences currently has a consensus price target of $95.06, indicating a potential upside of 9.40%. Abbott Laboratories has a consensus price target of $120.64, indicating a potential upside of 18.05%. Given Abbott Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Abbott Laboratories is more favorable than Edwards Lifesciences.
Edwards Lifesciences has a net margin of 23.01% compared to Abbott Laboratories' net margin of 13.96%. Edwards Lifesciences' return on equity of 22.86% beat Abbott Laboratories' return on equity.
79.5% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 1.3% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 1.1% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Edwards Lifesciences beats Abbott Laboratories on 12 of the 18 factors compared between the two stocks.
Get Edwards Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edwards Lifesciences Competitors List
Related Companies and Tools
